CELLINK and partner Prellis Biologics awarded Merck Innovation Award for cutting-edge technology designed to empower pharmaceutical research.
CELLINK began collaborating with Prellis Biologics to develop the Holograph X bioprinter in 2018, and the technology was recently recognized enabling innovative capabilities for the pharmaceutical industry.The Holograph X, a bioprinter that leverages high-resolution holographic stereolithography to bioprint small structures, earned CELLINK a top honor as an innovative medical device with the potential to change what’s possible in pharmaceutical medicine. In the award announcement, Merck senior investigator Tim Rhodes recognized CELLINK and California-based development partner Prellis